We are live on ! Find out more
OKYO

OKYO Pharma
OKYO

3 hedge funds and large institutions have $62K invested in OKYO Pharma in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0.14% more ownership

Funds ownership: 0% → 0.14% (+0.14%)

Holders
3
Holders Change
+3
Holders Change %
–
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$60.4K
2
UBS Group
UBS Group
Switzerland
+$8.25K
3
TRCT
Tower Research Capital (TRC)
New York
+$515

Top Sellers

No sellers this quarter

OKYO Hedge Fund Activity: Q2 2022 in Review

3 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q2 2022, worth a combined $62K.

Buyers outnumbered sellers: 3 funds opened new OKYO positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $60.4K.

  • 3 institutional investors held OKYO Pharma (OKYO) as of Q2 2022, up from 0 in Q1 2022.
  • Funds reported $62K of OKYO Pharma stock for Q2 2022.
  • 3 funds opened new OKYO Pharma positions in Q2 2022 and 0 closed out, a net change of +3 holders.
  • The largest OKYO Pharma buyer in Q2 2022 was Citadel Advisors, an estimated $60.4K added.

Based on aggregated 13F filings for Q2 2022.